anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Recently, the therapeutic results of lingual orthodontics have become similar to those produced by labial orthodontics. However, lingual appliances act differently. The application of force near the center of resistance and the distance between the lingual brackets leads to an increase in friction and, thus, an increase in the force applied during treatment. In addition, the contact of the lower incisors with the brackets of the upper incisors in the lingual technique can lead to the intrusion of these incisors. Therefore, these factors can be potential risks for apical root resorption and alveolar bone height in lingual orthodontics.

2D radiographs may not accurately depict the true amount of root resorption due to magnification errors and difficulties in obtaining repeatable images. Besides, conventional two-dimensional radiographs cannot accurately assess alveolar bone height in the anterior region. CBCT has proven to be valuable in diagnosing root resorption due to its capability to produce distortion-free images, as well as its ability to maintain a high level of reproducibility despite changes in tooth positions after treatment, with high sensitivity and specificity. On the other hand, the use of CBCT allows for an evaluation of alveolar bone height in the anterior region with high accuracy and precision.
The present invention relates to methods of producing recombinant molecules including the nucleotide sequence for the structure of the preS1 region of the surface glycoprotein of the hepatitis B virus, and to compositions of the molecules. Compositions of the recombinant molecules may include a promoter and a marker gene. Cloning vectors are used to incorporate the recombinant molecules into hosts. Cells infected with the chimeric vaccinia produce high levels of preS1 protein. Isolation and purification of the preS1-containing protein is facilitated by the use of a recombinant molecule in which the myristylation site has been deleted by a modification of the nucleotide sequence. The purified preS1-containing protein is useful for development of vaccines, diagnostic kits and therapies.
Obesity and metabolic syndrome represent a growing epidemic worldwide. Body weight is regulated through complex interactions between hormonal, neural and metabolic pathways and is influenced by numerous environmental factors. Imbalances between energy intake and expenditure can occur due to several factors, including alterations in eating behaviours, abnormal satiation and satiety, and low energy expenditure. The gut microbiota profoundly affects all aspects of energy homeostasis through diverse mechanisms involving effects on mucosal and systemic immune, hormonal and neural systems. The benefits of dietary fibre on metabolism and obesity have been demonstrated through mechanistic studies and clinical trials, but many questions remain as to how different fibres are best utilized in managing obesity. In this Review, we discuss the physiochemical properties of different fibres, current findings on how fibre and the gut microbiota interact to regulate body weight homeostasis, and knowledge gaps related to using dietary fibres as a complementary strategy. Precision medicine approaches that utilize baseline microbiota and clinical characteristics to predict individual responses to fibre supplementation represent a new paradigm with great potential to enhance weight management efficacy, but many challenges remain before these approaches can be fully implemented.
FIELD: medicine. ^ SUBSTANCE: invention relates to protein analogues of interferon-, in which asparagine in position 25, in accordance with numeration of amino acids in native interferon-, is deamidated, and cysteine in position 17, in accordance with numeration of amino acids in native interferon-, is deleted or substituted with neutral amino acid, which demonstrate higher levels of biological activity of native human interferon- and do not require HA for protein stabilisation. Deamidated product id suitable for wide-scale production for introduction into HA-containing or HA-non-containing therapeutic medications for treatment of diseases including disseminates sclerosis. Also claimed is method of peptide mapping by means of endoproteinase-C, which gives chromatographic profile of proteins with use of enzymatic breakdown with further RP-HPLC, is suitable for quality control as ID and/or quantitative test of deamidated products. ^ EFFECT: improvement of biological properties. ^ 21 cl, 16 dwg, 6 tbl
Participants in the foam rolling group will perform unilateral rolling of the hamstring musculature from ischial tuberosity to posterior knee in supine for 2 repetitions of 1 minute with 15 second rest between repetitions at a consistent cadence of 1 second superiorly and 1 second inferiorly. Subjects will be asked to adjust pressure as needed to maintain a consistent moderate pressure on the treatment area. Participants will use new and individually issued high density foam rollers that are 6" diameter x 36" length.
Pegylated liposomal doxorubicin (PLD) after induction chemotherapy in patients with metastatic breast cancer (MBC). Patients without disease progression following first-line induction chemotherapy consisting of three cycles of doxorubicin (75 mg/m2) followed by three cycles of docetaxel (100 mg/m2) both every 21 days, were randomized to PLD (40 mg/m2) every 28 days for six cycles or to observation.
Monoclonal neutralizing antibodies are disclosed that specifically bind to a Norovirus. In some embodiments, the Norovirus is a genogroup II Norovirus or a Genogroup II Norovirus. In some embodiments, the Norovirus is Norwalk virus. In some embodiments, the monoclonal antibodies specifically bind VP1. Also disclosed are compositions including the disclosed antibodies, nucleic acids encoding these antibodies, expression vectors including the nucleic acids, and isolated host cells that express the nucleic acids. The antibodies and compositions disclosed herein can be used for detecting the presence of a Norovirus in a biological sample, or detecting a Norovirus infection. In addition, the neutralization ability of the disclosed antibodies makes them ideal for treating a subject with a Norovirus infection. Thus, disclosed are methods of treating and/or preventing these infections.
Traditional rehabilitation training is designed according to postoperative orthopaedic rehabilitation guidelines. Traditional rehabilitation trainings include grip and pinch, wrist flexion with forearm pronated, wrist extension with forearm pronated, wrist flexion with forearm supinated, wrist extension with forearm supinated, prayer sign (wrist flexion), prayer sign (wrist extension), forearm pronation, forearm supination. Patients participated in 2 training sessions per week with at least 48 hours rest in between for continuous 6 weeks.
Tissue engineering combines bone marrow cells or mesenchymal stem cells (MSCs), synthetic scaffolds and molecular signals (growth or differentiating factors) in order to form hybrids constructs. For bone reconstruction purposes, human MSCs have been seeded and cultured on porous calcium phosphate ceramics in osteogenic media. Some clinical studies with low numbers of patients have been reported using this approach but the outcomes were inconsistent with low efficacy in bone regeneration. The reasons of the limited clinical success may be due to several bottlenecks in the multidisciplinary field of bone tissue engineering. The association in vitro of biomaterials and osteoprogenitor cells raises technical challenges and regulatory and ethic issues for the implementation of clinical trials, whereas the expansion of MSCs is now possible in GMP Facility.

The expected results are to obtain bone consolidation thus healing of delayed union or non-union, as proven by imaging techniques, without using bone graft. This will prove the efficacy of the proposed IMP based on pluripotent MSCs expanded in a GMP facility and mixed with granulated biphasic calcium phosphate in the surgical setting before implantation. No expected complications related to the procedure are expected. Changes in serum levels of bone turnover markers will be described.
This invention relates to novel mammalian excitatory amino acid transporter proteins and genes encoding such proteins. The invention is directed towards the isolation, characterization and use of human excitatory amino acid transporter proteins for pharmacological screening of analogues, agonists, antagonists, inhibitors, modulators and facilitators of excitatory amino acid transport in a variety of tissues, particularly neuronal tissues. This invention provides isolated nucleic acid encoding a novel excitatory amino acid transporter subtype that is specifically expressed in retina. Also provided are recombinant expression constructs capable of expressing this novel transporter in transformed prokaryotic and eukaryotic cells, and also provides such transformed cell cultures producing the novel human transporter. Purified transporter protein and membranes comprising the transporter protein are also provided. The invention provides methods of screening compounds in vitro for transporter binding properties using said preparations of protein and membranes from transformed cell cultures, as well as from amphibian oocytes expressing the human transporter protein provided herein.
Iodine povacrylex in isopropyl alcohol (Duraprep 3M) This is considered a standard of care in our hospital as many other institutions. It's efficacy and safety have been demonstrated.
At recruitment, participants will be dispensed new medication in Rx Cap pill bottles provided with PMLs in English. After 2 weeks, a home visit will be conducted, where the English PMLs will be switched out with bilingual PMLs. A final home visit will be done after another 2 weeks, and the labels will be switched back to the standard-issue PMLs issued by SGH, and the Rx Cap pill bottles will be retrieved.
Orbital tumors are divided anatomically into intraconal and extraconal depending on their relationship with the muscle cone which is further classified into anterior and posterior orbital tumors. Excision of orbital tumors is considered a challenge for the surgeon. This is due to the complex structure of the orbit. The orbital cavity is narrow that does not allow adequate exposure. Furthermore, the orbit is full of vital structures which require careful manipulation. Many surgical approaches for excision of these tumors have been described. These approaches do not allow access to all orbital quadrants. Furthermore, some of these approaches are technically difficult, associated with long morbidity and post operative pain due to the osteotomy, having high rate of complications or having unacceptable cosmetic appearance. Few studies with limited number of patients have used transconjunctival approach in management of orbital tumors All patients with orbital tumor will be managed by the transconjunctival incisional or excisional biopsy according to the suggested nature of the tumor being benign or malignant as well as the site of the tumor using the clinicoradiological finding. In case of intraconal tumors, the mass will be approached via the transconjunctival approach but if the mass is out of reach via this approach, lateral orbitotomy approach will be used as an alternative procedure to perform the predetermined decision. This allows detection of the intraconal tumor criteria that could be excised safely via this approach
The present invention relates to fusion proteins comprising a cell surface marker specific VHH. In particular, the invention relates to bispecific VHH adaptor proteins, i.e. fusion proteins comprising an adeno-associated virus (AAV) specific VHH linked to a cell surface marker specific VHH. Moreover, the invention relates to a recombinant AAV which comprises a fusion protein in which a cell surface marker specific VHH is integrated into a capsid protein of the AAV. Also nucleotide sequences encoding such fusion proteins, vectors are contemplated. The invention moreover refers to uses of the fusion proteins and nucleic sequences for gene therapy.
The invention relates to a preparation method for a general flavone extract, in particular to a preparation method for a reproducible general flavone extract from seed coats of perennial xylophyta peony. The general flavone extract from the seed coats of the peony is prepared by extracting and purifying residual seed coats generated during the peony seed oil machining process. The preparation method comprises the following steps of: crushing dry seed coats of the peony by taking the dry seed coats of the peony as raw materials, and then, adding to an extraction kettle; extracting by using water or water-contained alcohol; merging extracts; concentrating to obtain extractum; dissolving the extractum by adding the water or the water-contained alcohol; centrifuging to obtain supernate; eluting the supernate by using the water or the water-contained alcohol through a polyamide resin column; then, eluting with alcohol or the water-contained alcohol; collecting eluent; and concentrating and drying the eluent to obtain the general flavone extract from the seed coats of the peony. Flavonoid matter is extracted from useless seed coats of the peony. During the whole preparation process, the process is simple, and the energy consumption is low. Used solvents are the alcohol and the water, can be recycled, are pollution-free and are better in environmental benefit. The general flavone content in the obtained extract is high and is better in economic benefit and social benefit.
NCWS patients will undergo a Double-Blind Wheat Challenge DBWC with an ancient diploid wheat (TM) or a modern hexaploid wheat (TA). This DBWC will be performed with flour packets coded A or B, each containing respectively one of the wheat varieties. Packets A or B will be given for 1 week and then, after 1 week of washout (or until patients report complete well-being), the patients will receive the other packets for another 1 week (cross-over design).
Marathon running or other forms of strenuous exercise have been reported as a rare cause of acute pancreatitis. Theories as to the mechanism of acute pancreatitis include microvascular ischaemia due to dehydration or repetitive trauma to the pancreas. We report a case of a healthy woman in her 30s who developed abdominal pain, nausea and vomiting after a 32 km marathon training run. She was found to have elevated lipase and inflammation of the pancreatic tail with associated pericolic and pelvic free fluid on CT scan. Workup including abdominal ultrasound and magnetic resonance cholangiopancreatography (MRCP) did not reveal biliary or pancreatic duct pathology. She improved with conservative management. These findings support the hypothesis of exercise-induced pancreatitis from long-distance running.
PROBLEM TO BE SOLVED: To obtain a hair grower by including a specific amount of a volatile solvent, water, a pH adjustor and minoxidil so as to be excellent in the selective absorbability of the minoxidil into the hair papillae when administered to the scalp while securing the preservability of the minoxidil. SOLUTION: This hair grower is obtained by including (A) pref. 50-99 v/v% of a volatile solvent such as ethyl alcohol, (B) water, (C) a pH adjustor such as phosphoric acid and (D) pref. 0.1-5 wt.% of minoxiclil, and pref. further at least one kind of ingredient selected from 2-8C polyhydric alcohols, polyethylene glycol and fatty acid esters. It is preferable that this hair grower has <=pH 4.8 when diluted ten-fold with purified water before applied to the skin; therefore the amount of the ingredient C to be formulated is pref. set at 0.01-5 wt.% based on the final hair grower.
Part 1: INCAGN02385 at the protocol-defined starting dose administered every 2 weeks (Q2W), with dose escalation to determine the maximum tolerated dose or pharmacologically active dose. Part 2: INCAGN02385 administered Q2W or Q4W at the recommended dose(s) from Part 1.
This is a 6-month, randomized, controlled investigation measuring the effect of increased clinical contact and personalized recommendations from a health coach, compared to standard physician counseling on adherence to consensus-based, brain health recommendations, including 80 patients with either subjective cognitive decline, MCI, or early dementia enrolled from a hospital-based memory disorders clinic, or, with risk factors for dementia enrolled from a hospital-based primary care clinic. Participants and caregivers in the health coach arm work with a health coach within their respective practice, called the a "brain health champion" (BHC), through weekly motivational phone calls every 6 weeks. In the encounters and visits, BHCs and patients/caregivers work together to establish, update, and achieve personalized, attainable lifestyle goals. Participants in the control arm receive standard counseling and education from providers during routine clinic visits. Changes in physical activity, dietary pattern, and social and cognitive activities are measured using questionnaires validated in cognitively impaired and normal populations. Other outcomes include measures of quality of life (QOL), cognitive function, neuropsychiatric status, sleep quality, and behavior. Follow-up assessments are also completed at 6 months post-intervention, with some patients receiving "booster" encounters to assess the maintenance of behaviors.
<P>PROBLEM TO BE SOLVED: To obtain a pharmaceutical composition containing a glycoprotein hormone analog having improved stability with keeping at least a part of biological activity of the corresponding glycoprotein.  <P>SOLUTION: The glycoprotein hormone is selected from the group consisting of human chorionic gonadotropin (hCG), human lutenizing hormone (hLH), human follicle stimulating hormone (hFSH), human thyroid stimulating hormone (hTSH) and their functional variants having an α-subunit and a β-subunit. By modifying an amino acid sequence, a disulfide bond is created between cystein in the α-subunit and cystein in the β-subunit. The two cysteins are exposed between two residues at the position of natural cystein residue of the glycoprotein hormone and do not expose outside of the outermost cystein unit of the corresponding natural cystein. The pharmaceutical composition contains effective amount of the glycoprotein hormone and includes pharmaceutically permissible formulations.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Continuous clinical evaluation and care adjustment in virtual reality (VR) or augmented reality (AR) environments is provided. In various embodiments, an evaluation protocol is read from a datastore. The evaluation protocol comprises a plurality of tasks. Each of the plurality of tasks are presented to a user via a virtual or augmented reality display. Positional data are collected from a plurality of sensors. The positional data is received at a remote server and compared to the evaluation protocol to determine a score reflecting the clinical evaluation of the user based on the performance of the plurality of tasks. Whether the score differs from a predetermined threshold is determined at the remote server. A healthcare regimen is adjusted when the score differs from the threshold.
Administered at time 0 min and 300 min. Cellulose was used as the placebo.
###  Parenteral (IM or IV) Administration

20 to 40 mg/kg/day in 3 or 4 equal doses. The higher doses would be used for more severe infections. Clindamycin should be dosed based on total body weight regardless of obesity. As an alternative to dosing on a body weight basis, pediatric patients may be dosed on the basis of square meters body surface: 350 mg/m 2/day for serious infections and 450 mg/m 2/day for more severe infections. 

Parenteral therapy may be changed to oral CLEOCIN PEDIATRIC ®Flavored Granules (clindamycin palmitate hydrochloride) or CLEOCIN HCl ®Capsules (clindamycin hydrochloride) when the condition warrants and at the discretion of the physician. 

In cases of β-hemolytic streptococcal infections, treatment should be continued for at least 10 days.
Sulindac is a non-steroidal, anti-inflammatory indene derivative designated chemically as (Z)-5-fluoro-2-methyl-1-[[p-(methylsulfinyl)phenyl]methylene]-1H-indene-3-acetic acid. It is not a salicylate, pyrazolone or propionic acid derivative. Its empirical formula is C20H17FO3S, with a molecular weight of 356.42. Sulindac, a yellow crystalline compound, is a weak organic acid practically insoluble in water below pH 4.5, but very soluble as the sodium salt or in buffers of pH 6 or higher.

Sulindac tablets are available in 150 and 200 mg tablets for oral administration. Each tablet contains the following inactive ingredients: magnesium stearate, microcrystalline cellulose, and pregelatinized starch.

Following absorption, sulindac undergoes two major biotransformations – reversible reduction to the sulfide metabolite, and irreversible oxidation to the sulfone metabolite. Available evidence indicates that the biological activity resides with the sulfide metabolite.

The structural formulas of sulindac and its metabolites are:
This part covers the list for comprehensive medication use at admission, medication reconciliation and medication review at preoperative surgical ward, postoperative intensive care, postoperative surgical ward and discharge made by clinical pharmacist. Clinical pharmacist made recommendation about drug related problems regarding solutions, record intervention type and problem status differently from observational part. As a component of the risk analysis model the affect of clinical pharmacist was shown clearly. Patients quality of life, nutritional status, cognitive functions and frailty status also recorder at admission, discharge and 1 month after surgery.
Patients with unresectable hepatocellular carcinoma (HCC) in this group will receive drug-eluting bead transarterial chemoembolization (DEB-TACE).And then, they will receive sorafenib (400 mg/d, po, bid) one week after DEB-TACE therapy. The second DEB-TACE will be performed after one month later the first DEB-TACE. Lenvatinib will be taken orally for six months, untill tumor progression, or intolerable adverse reactions.
The study will be conducted in the United States at up to 5 centers. The study will enroll up to 600 subjects. The number of subjects was chosen to allow evaluation of screening and diagnostic patients with a variety of breast densities (fatty, scattered densities, heterogeneously dense or extremely dense) and women with a range of breasts sizes that fit on the current detector. The evaluation of pain reduction will be the primary endpoint, while examining the potential of increased tissue capture without a compromise in image quality will be assessed as secondary endpoints. The enrollment will be consecutive for subjects who sign informed consent to participate. Women participating in the study will present for a screening or diagnostic imaging exam.